Aliases & Classifications for Agoraphobia

About this section

Aliases & Descriptions for Agoraphobia:

Name: Agoraphobia 11 13 48 37 66
 
Fear of Open Spaces 11

Classifications:



External Ids:

Disease Ontology11 DOID:593
ICD1028 F40.0, F40.00
MeSH37 D000379
NCIt43 C34362

Summaries for Agoraphobia

About this section
Disease Ontology:11 A phobic disorder involving the specific anxiety about being in a place or situation where escape is difficult or embarrassing or where help may be unavailable.

MalaCards based summary: Agoraphobia, also known as fear of open spaces, is related to panic disorder and anxiety disorder, and has symptoms including death anxiety An important gene associated with Agoraphobia is SLC6A4 (Solute Carrier Family 6 Member 4), and among its related pathways are Monoamine Transport and SIDS Susceptibility Pathways. The drug alprazolam has been mentioned in the context of this disorder. Affiliated tissues include brain, thyroid and cortex, and related mouse phenotypes are behavior/neurological and nervous system.

Wikipedia:69 Agoraphobia is an anxiety disorder characterized by symptoms of anxiety in situations where the person... more...

Related Diseases for Agoraphobia

About this section

Diseases related to Agoraphobia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 75)
idRelated DiseaseScoreTop Affiliating Genes
1panic disorder11.4
2anxiety disorder10.8
3conjunctival degeneration10.6HTR1A, SLC6A4
4central sleep apnea10.6HTR1A, SLC6A4
5dental fluorosis10.6HTR1A, SLC6A4
6anosognosia10.5HTR1A, SLC6A4
7tinea pedis10.5HTR1A, SLC6A4
8intrahepatic gall duct cancer10.5MAOA, SLC6A4
9chagas disease10.4MAOA, SLC6A4
10phaeohyphomycosis10.4HTR1A, SLC6A4
11viral gastritis10.4HTR1A, SLC6A4
12hemorrhagic cystitis10.4MAOA, SLC6A4
13intermittent explosive disorder10.4MAOA, SLC6A4
14hallucinogen dependence10.4OPRK1, SLC6A4
15tongue disease10.4MAOA, SLC6A4
16vogt-koyanagi-harada disease10.4MAOA, SLC6A4
17lymphadenitis10.4MAOA, SLC6A4
18social phobia10.4
19maternal uniparental disomy of chromosome 1310.3MAOA, SLC6A4
20personality disorder10.3
21phlegmonous dacryocystitis10.3MAOA, SLC6A4
22laryngeal adductor paralysis10.2HTR1A, SLC6A4
23vernal conjunctivitis10.2HTR1A, SLC6A4
24vulvar disease10.2MAOA, SLC6A4
25heroin dependence10.2OPRK1, SLC6A4
26obsessive-compulsive disorder10.2
27idiopathic neonatal atrial flutter10.2HTR1A, MAOA, SLC6A4
28pyromania10.2HTR1A, MAOA, SLC6A4
29meckel's diverticulum10.2HTR1A, MAOA, SLC6A4
30obsessive-compulsive personality disorder10.2HTR1A, MAOA, SLC6A4
31hypoglycemic coma10.2HTR1A, MAOA, SLC6A4
32generalized anxiety disorder10.2
33chronic cervicitis10.2HTR1A, MAOA, SLC6A4
34pyoderma gangrenosum10.2HTR1A, MAOA, SLC6A4
35avoidant personality disorder10.2HTR1A, MAOA, SLC6A4
36purpura10.2HTR1A, MAOA, SLC6A4
37aicardi-goutieres syndrome 210.2HTR1A, MAOA, SLC6A4
38ring chromosome 14 syndrome10.2CTU2, MAOA
39albinism, oculocutaneous, type v10.1HTR1A, MAOA, SLC6A4
40sudden infant death syndrome10.1HTR1A, MAOA, SLC6A4
41eating disorder10.0
42craniosynostosis, adelaide type10.0HTR1A, MAOA, SLC6A4
43acinar cell carcinoma10.0MAOA, SLC6A4
44separation anxiety disorder10.0
45thyroiditis10.0
46parkinson disease, late-onset9.9HTR1A, MAOA, SLC6A4
47hypochondriasis9.9
48melancholia9.9
49irritable bowel syndrome9.9
50narcolepsy 29.8HTR1A, MAOA, OPRK1, SLC6A4

Graphical network of the top 20 diseases related to Agoraphobia:



Diseases related to agoraphobia

Symptoms for Agoraphobia

About this section

UMLS symptoms related to Agoraphobia:


death anxiety

Drugs & Therapeutics for Agoraphobia

About this section

Drugs for Agoraphobia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 11)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
ClonazepamPhase 4311622-61-32802
Synonyms:
1,3-Dihydro-5-(o-chlorophenyl)-7-nitro-3H-1,4-benzodiazepin-2-one
1,3-Dihydro-7-nitro-5-(2-chlorophenyl)-2H-1,4.benzodiazepin-2-one
1,3-dihydro-7-Nitro-5-(2-chlorophenyl)-2H-1,4.benzodiazepin-2-one
106955-87-7
1622-61-3
5-(2-Chloro-phenyl)-7-nitro-1,3-dihydro-benzo[e][1,4]diazepin-2-one
5-(2-Chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one
5-(2-Chlorophenyl)-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one
5-(2-Chlorophenyl)-7-nitro-1H-benzo[e][1,4]diazepin-2(3H)-one
5-(2-Chlorophenyl)-7-nitro-3H-1,4-benzodiazepin-2(1H)-one
5-(2-chlorophenyl)-7-nitro-1,3-dihydro-1,4-benzodiazepin-2-one
5-(O-Chlorophenyl)-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one
5-(o-Chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one
5-(o-Chlorophenyl)-7-nitro-1H-1,4-benzodiazepin-2(3H)-one
5-(o-chlorophenyl)-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one
5-24-04-00351 (Beilstein Handbook Reference)
7-Nitro-5-(2-chlorophenyl)-3H-1,4-benzodiazepin-2(1H)-one
AC-15733
AC1L1EI2
Alti-Clonazepam
Antelepsin
Antilepsin
BAS 00308658
BIDD:PXR0144
BRN 0759557
C1277_SIGMA
C15H10ClN3O3
CHEBI:3756
CHEMBL452
CID2802
CLONAZEPAM
Chlonazepam
Cloazepam
Clonazepam (JP15/USP/INN)
Clonazepam [USAN:INN:BAN:JAN]
Clonazepamum
Clonazepamum [INN-Latin]
Clonex
Clonopin
D00280
D002998
DB01068
DEA No. 2737
 
DF2374250
DivK1c_000973
EINECS 216-596-2
HMS2093H22
HMS503C07
HSDB 3265
I14-1364
IDI1_000973
Iktorivil
Jsp003251
KBio1_000973
Kenoket
Klonopin
Klonopin (TN)
Klonopin Rapidly Disintegrating
LS-34156
LS-34260
Landsen
Lktorivil
Lonazep
Melzap
MolPort-001-729-088
NINDS_000973
NIOSH/DF2374250
NSC 179913
NSC179913
Oprea1_168772
Paxam
RO4023
Ravotril
Rivatril
Rivoril
Rivotril
Ro 4-8180
Ro 4023
Ro 5-4023
Ro 5-4023/B-7
Ro 54023
Ro-5-4023
Solfidin
UNII-5PE9FDE8GB
WLN: T67 GMV JN IHJ CNW KR BG
ZINC03813003
clonazepam
2
sertralinePhase 429079617-96-268617
Synonyms:
(+)-Sertraline
(1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalen-1-amine
(1S,4S)-Sertraline
(1S-cis)-1,2,3,4-Tetrahydro-4-(3,4-dichlorophenyl)-N-methyl-1-naphthalenamine
(1S-cis)-4-(3,4-Dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine
79559-97-0 (Hydrochloride)
79617-96-2
AB00514002
AB1004870
AC-15639
AC1L2A41
AC1Q3O5N
AC1Q3XJU
Apo-Sertraline
BIDD:GT0768
BIDD:PXR0193
BPBio1_001285
BRD-K82036761-003-02-1
BRN 5753709
BSPBio_001167
BSPBio_002698
C07246
C17H17Cl2N
CHEBI:9123
CHEMBL809
CID68617
CP 51974
Cp 51974
D02360
DB01104
DB08567
FT-0081122
HSDB 7037
KBio3_001918
 
KBioGR_001724
LS-94179
Lustral
MLS001195647
MLS002222308
MolPort-002-885-860
NCGC00092386-03
NCGC00092386-04
NCGC00092386-05
NCGC00092386-06
NCGC00092386-07
NCGC00092386-08
NCGC00092386-09
Prestwick3_001014
SMR000596516
SPBio_000385
SRE
Sertralina
Sertralina [Spanish]
Sertraline
Sertraline (INN)
Sertraline Hydrochloride
Sertraline [INN:BAN]
Sertraline [Zoloft]
Sertraline hydrochloride
Sertralinum
Sertralinum [Latin]
Spectrum2_000493
Spectrum3_001079
Spectrum4_001232
Sultamicillin Tosylate
UNII-QUC7NX6WMB
Zoloft
cis-(+)-Sertraline
sertraline
sertraline (Zoloft)
3
AlprazolamPhase 4, Phase 16628981-97-72118
Synonyms:
28981-97-7
611026_ALDRICH
611026_FLUKA
8-Chloro-1-methyl-6-(phenyl-d5)-4H-(1,2,4)triazolo[4,3-a][1,4]benzodiazepine
8-Chloro-1-methyl-6-phenyl-4H-S-triazolo(4,3-a)(1,4)benzodiazepine
8-Chloro-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine
8-Chloro-1-methyl-6-phenyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepine
8-Chloro-1-methyl-6-phenyl-4H-s-triazolo(4,3-alpha)(1,4)benzodiazepine
8-Chloro-1-methyl-6-phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepine
A6551_FLUKA
A6551_SIGMA
A8800_SIGMA
AC-18721
AC1L1CYL
AKOS005066050
AP-1002
AZ-002
Alcelam
Algad
Alpaz
Alphapharm Brand of Alprazolam
Alplax
Alpram
Alprax
Alprazolam
Alprazolam (JP15/USP/INN)
Alprazolam Alphapharm Brand
Alprazolam Apotex Brand
Alprazolam Kenral Brand
Alprazolam Novopharm Brand
Alprazolam Nu-Pharm Brand
Alprazolam Orion Brand
Alprazolam Pfizer Brand
Alprazolam Temmler Brand
Alprazolam [USAN:INN:BAN:JAN]
Alprazolam extended release tablets
Alprazolam intensol
Alprazolam solution
Alprazolam-d5
Alprazolamum
Alprazolamum [INN-Latin]
Alprazolan
Alpronax
Alprox
Alviz
Alzam
Alzolam
Alzon
Anpress
Apo Alpraz
Apo-Alpraz
ApoAlpraz
Apotex Brand of Alprazolam
Arzneimittelwerk Dresden Brand of Alprazolam
Azor
BIDD:GT0475
BIDD:PXR0150
BRN 1223125
Bestrol
Bio-0790
C06817
CHEBI:2611
CHEMBL661
CID2118
CPD000149316
Cassadan
Constan
D 65MT
D-65MT
D000525
D00225
D65MT
DB00404
DEA No. 2882
EINECS 249-349-2
Esparon
Frontal
Gen-Alprazolan
HMS2051A10
 
HSDB 7207
Helex
I14-7472
Intensol
Kenral Brand of Alprazolam
Ksalol
LS-156344
MLS000559000
MLS000759485
Mialin
MolPort-002-507-836
NCGC00159466-02
NCGC00159466-03
Neurol
Niravam
Novo Alprazol
Novo-Alprazol
NovoAlprazol
Novopharm Brand of Alprazolam
Nu Alpraz
Nu Pharm Brand of Alprazolam
Nu-Alpraz
Nu-Pharm Brand of Alprazolam
NuAlpraz
Orion Brand of Alprazolam
Panistat
Panix
Pfizer Brand of Alprazolam
Pharnax
Prazam
Prazolan
Prinox
Ralozam
Relaxol
Restyl
SAM001246696
SMR000149316
STK590494
Solanax
Staccato-alprazolam
TGAR01P
TUS-1
Tafil
Tafil D
Temmler Brand of Alprazolam
Tensivan
Tranax
Trankimazin
Tranquinal
Tricalma
Tus 1
U 31889
U-31,889
U-31889
U31,889
UNII-YU55MQ3IZY
Unilan
Valeans
Xanagis
Xanax
Xanax (TN)
Xanax TS
Xanax XR
Xanolam
Xanor
ZINC00000903
Zacetin
Zanapam
Zaxan
Zenax
Zolam
Zolan
Zolarem
Zoldac
Zoldax
Zopax
Zopic
Zotran
alprazolam
nchembio747-comp35
4
SerotoninPhase 4, Phase 3351050-67-95202
Synonyms:
3-(2-Aminoethyl)-1H-indol-5-ol
3-(2-Aminoethyl)indol-5-ol
3-(b-Aminoethyl)-5-hydroxyindole
5-HT
5-HTA
5-Hydroxy-3-(b-aminoethyl)indole
 
5-Hydroxy-tryptamine
5-Hydroxyltryptamine
5-Hydroxytriptamine
5-Hydroxytryptamine
Antemovis
DS substance
Enteramin
Enteramine
5
paroxetinePhase 4, Phase 322361869-08-743815
Synonyms:
(-)-(3S,4R)-4-(P-Fluorophenyl)-3-((3,4-(methylenedioxy)phenoxy)methyl)piperidine
(-)-(3S,4R)-4-(p-Fluorophenyl)-3-((3,4-(methylenedioxy)phenoxy)methyl)piperidine
(-)-(3S,4R)-4-(p-Fluorophenyl)-3-((3,4-methylenedioxy)phenoxy)methyl)piperidine
(-)-Paroxetine
(-)-trans-4-(4-Fluorophenyl)-3-(3,4-methylenedioxyphenoxymethyl)piperidine
(-)-trans-4-(p-fluorophenyl)-3-[[3,4-(methylenedioxy)phenoxy]methyl]-piperidine
(3S,4R)-3-(1,3-benzodioxol-5-yloxymethyl)-4-(4-fluorophenyl)piperidine
(3S,4R)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine
(3S-trans)-3-((1,3-Benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)piperidine
(3S-trans)-3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)piperidine
(3S-trans)-3-[(1,3-Benzodioxol-5-yl-oxy)methyl]-4-(4-fluorophenyl)piperidine
110429-35-1
3-(Benzo[1,3]Dioxol-5-Yl-Oxymethyl)-4-(4-Fluoro-Phenyl)-Piperidine Hydrochloride
61869-08-7
63952-24-9
64006-44-6 (maleate)
78246-49-8 (hydrochloride)
AB00514724
AC1L2AKL
AC1Q1H18
AC1Q4LV6
Aropax
BIDD:GT0673
BPBio1_000949
BRD-K37991163-003-02-7
BRL 29060
BRL-29060
BSPBio_000861
C07415
C19H20FNO3
CHEBI:7936
CHEMBL490
CID43815
Casbol
D02362
DB00715
DivK1c_006884
FG 7051
FG-7051
FT-0085087
Frosinor
 
HMS2090H05
I14-7752
KBio1_001828
KBio2_002232
KBio2_004800
KBio2_007368
KBioSS_002232
LS-114249
MolPort-003-849-791
Motivan
NCGC00025355-02
NCGC00025355-03
NCGC00025355-04
NCGC00025355-05
NCGC00025355-06
NCGC00025355-07
NCGC00025355-08
NNC-20-7051
Paroxetina
Paroxetina [INN-Spanish]
Paroxetine
Paroxetine (TN)
Paroxetine (USP/INN)
Paroxetine Hcl
Paroxetine [USAN:INN:BAN]
Paroxetinum
Paroxetinum [INN-Latin]
PaxPar
Paxetil
Paxil
Paxil CR
Pexeva
Prestwick3_000851
Seroxat
Seroxat CR
SpecPlus_000788
Spectrum5_001665
Spectrum_001752
TL8003967
UNII-41VRH5220H
[3H]Paroxetine
paroxetine
6
DopaminePhase 4367851-61-6, 62-31-7681
Synonyms:
(3H)-Dopamine
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-Dihydroxyphenyl)ethylamine
2-(3,4-dihydroxyphenyl)ethylamine
2-benzenediol
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3,4-dihydroxyphenethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)-Pyrocatechol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
4-(2-aminoethyl)-pyrocatechol
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
ASL 279
BIDD:ER0506
BPBio1_001123
BSPBio_001932
Biomol-NT_000001
C03758
CHEBI:18243
CHEMBL59
CID681
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine [INN:BAN]
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydroxytyramin
Hydroxytyramine
IDI1_000780
IP 498
Intropin
Intropin [*hydrochloride*]
KBio1_000780
 
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L-DOPAMINE
L000232
LDP
LS-159
Lopac-H-8502
Lopac0_000586
Medopa (TN)
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
SPECTRUM1505155
ST048774
STK301601
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
Spectrum_001012
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
cMAP_000036
cMAP_000065
dopamine
hydroxytyramine
intropin
m-Hydroxytyramine hydrochloride
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
7
CycloserinePhase 210368-41-7401, 6234
Synonyms:
(+)-4-Amino-3-isoxazolidinone
(+)-Cycloserine
(4R)-4-Amino-3-isoxazolidinone
(4R)-4-amino-1,2-oxazolidin-3-one
(4R)-4-aminoisoxazolidin-3-one
(R)-(+)-4-Amino-3-isoxazolidinone
(R)-(+)-Cycloserine
(R)-4-AMINO-ISOXAZOLIDIN-3-ONE
(R)-4-AMINO-isoxazolidin-3-one
(R)-4-Amino-3-isoxazolidinone
(R)-4-Amino-3-isoxazolidone
(R)-Cycloserine
1pb9
3-Isoxazolidinone, 4-amino-, (+)- (8CI)
3-Isoxazolidinone, 4-amino-, (4R)- (9CI)
3-Isoxazolidinone, 4-amino-, (R)
3-Isoxazolidinone, 4-amino-, D
30020_FLUKA
30020_SIGMA
4-27-00-05549 (Beilstein Handbook Reference)
4AX
68-41-7
AB00443920
AC-4721
AC1L1M33
AC1Q4UA7
AI3-50153
BB_NC-1631
BIDD:GT0707
BPBio1_001252
BRN 0080798
BSPBio_001138
BSPBio_002121
C 3909
C-9390
C-9400
C08057
C3909_SIGMA
C3H6N2O2
C6880_SIGMA
C7670_SIGMA
CAS-339-72-0
CAS-68-41-7
CHEBI:40009
CHEMBL771
CID6234
CPD-2482
CPD000058313
Cicloserina
Cicloserina [INN-Spanish]
Cicloserina [Italian]
Closerin
Closina
Cyclo-D-serine
Cyclorin
Cycloserine
Cycloserine (JP15/USP/INN)
Cycloserine [INN:BAN:JAN]
Cycloserinum
Cycloserinum [INN-Latin]
D-(+)-Cycloserine
D-4-Amino-3-isossazolidone
D-4-Amino-3-isossazolidone [Italian]
D-4-amino-3-Isoxazolidinone
D-4-amino-3-Isoxazolidone
D-4-amino-3-isoxazolidinone
D-4-amino-3-isoxazolidone
D-CS
D-Cycloserine
D-Cycloserine synth. BP 88
D-Cycloserine, synthetic
D-Oxamicina
D-Oxamycin
D-amino-3-isoxazolidinone
D-cycloserine
D00877
DB03123
DCS
DL-Cycloserine
DRG-0195
DivK1c_000098
E-733-A
EINECS 200-688-4
 
EU-0100252
FA6C7F8B-D080-4EA3-978F-1ECFB5A29D09
Farmiserina
HMS1571I20
HMS1920C06
HMS2051C15
HMS2091I14
HMS500E20
HSDB 3218
I-1431
IDI1_000098
K-300
KBio1_000098
KBio2_001340
KBio2_003908
KBio2_006476
KBio3_001341
KBioGR_000890
KBioSS_001340
L-Cycloserine
LMPK14000007
LS-86757
Lopac-C-1159
Lopac-C-3909
Lopac-C-7005
Lopac0_000252
MLS000758215
MLS001423962
Micoserina
Miroserina
Miroseryn
MolPort-000-858-643
NCGC00015213-01
NCGC00015213-02
NCGC00015213-03
NCGC00016306-01
NCGC00016306-02
NCGC00016306-03
NCGC00016306-05
NCGC00093713-01
NCGC00093713-02
NINDS_000098
NSC 154851
Novoserin
Orientomycin
Oxamicina
Oxamicina [Italian]
Oxamycin
PA 94
PA-94
Prestwick0_001089
Prestwick1_001089
Prestwick2_001089
Prestwick3_001089
R(+)-4-Amino-3-isoxazolidinone
R-(+)-Cycloserine
R-4-Amino-3-isoxazolidinone
RO-1-9213
Ro-1-9213
S1998_Selleck
SAM001247014
SAM002264599
SC-49088
SMP1_000167
SMR000058313
SPBio_000008
SPBio_003029
SPECTRUM1500215
Seromycin
Seromycin (TN)
Spectrum2_000084
Spectrum3_000371
Spectrum4_000305
Spectrum5_000797
Spectrum_000860
Tebemicina
Tisomycin
UNII-95IK5KI84Z
Wasserina
alpha-Cycloserine
cyclo-D-Serine
cycloserine
orientomycin
α-Cycloserine
8
Adenosine38858-61-760961
Synonyms:
(2R,3R,4S,5R)-2-(6-Aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
(2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
1-(6-Amino-9H-purin-9-yl)-1-deoxy-beta-D-Ribofuranose
1-(6-Amino-9H-purin-9-yl)-1-deoxy-beta-delta-Ribofuranose
1odi
2fqy
2gl0
30143-02-3
4-Aminopyrazolo[3,4-d]pyrimidine ribonucleoside
46946-45-6
46969-16-8
58-61-7
6-Amino-9-.beta.-ribofuranosyl-9H-purine
6-Amino-9-beta-D-ribofuranosyl-9H-purine
6-Amino-9beta-D-ribofuranosyl-9H-purine
6-Amino-9beta-delta-ribofuranosyl-9H-purine
9-(beta-D-Arabinofuranosyl)adenine
9-beta-D-Arabinofuranosyladenine
9-beta-D-Ribofuranosidoadenine
9-beta-D-Ribofuranosyl-9H-purin-6-amine
9-beta-D-Ribofuranosyladenine
9-beta-delta-Arabinofuranosyladenine
9-beta-delta-Ribofuranosidoadenine
9-beta-delta-Ribofuranosyl-9H-purin-6-amine
9-beta-delta-Ribofuranosyladenine
9beta-D-Ribofuranosyladenine
9beta-D-ribofuranosyl-9H-Purin-6-amine
9beta-delta-Ribofuranosyladenine
9beta-delta-ribofuranosyl-9H-Purin-6-amine
A0152
A4036_SIGMA
A9251_SIGMA
AC1L1U8O
AC1Q1ID3
AC1Q52XU
ADN
AI3-52413
Ade-Rib
Ade-rib
Adenin riboside
Adenine 9-beta-D-arabinofuranoside
Adenine deoxyribonucleoside
Adenine nucleoside
Adenine riboside
Adenine-9-beta-D-ribofuranoside
Adenine-9beta-D-Ribofuranoside
Adenine-9beta-delta-Ribofuranoside
Adenocard
Adenocard (TN)
Adenocard, Adenosine
Adenocor
Adenoscan
Adenoscan (TN)
Adenosin
Adenosin [German]
Adenosina
Adenosine (JAN/USP)
Adenosine [USAN:BAN]
Adenosine, homopolymer
Adenosinum
Adensoine
Adenyldeoxyriboside
Ado
Adénosine
BB_NC-0565
BSPBio_001796
Bio1_000437
 
Bio1_000926
Bio1_001415
Boniton
C00212
CCRIS 2557
CHEBI:16335
CHEMBL477
CID60961
Caswell No. 010B
D000241
D00045
DB00640
Deoxyadenosine
Desoxyadenosine
EA6C60C2-6AFB-4264-A2F0-541373DB950E
EINECS 200-389-9
FT-0082881
HMS1920A13
HMS2091G13
KBio3_001296
LS-15085
MEDR-640
MLS000069638
MLS002153227
MolPort-001-838-229
Myocol
NCGC00023673-03
NCGC00023673-04
NCGC00023673-05
NCGC00023673-06
NCGC00023673-07
NSC 627048
NSC 7652
NSC627048
NSC7652
Nucleocardyl
Pallacor
Polyadenosine
Polyriboadenosine
S1647_Selleck
SDCCGMLS-0003108.P003
SMR000058216
SPBio_001194
SPECTRUM1500107
SR 96225
SR-96225
SUN-Y4001
Sandesin
Spectrum2_001257
Spectrum3_000288
TL8003749
UNII-K72T3FS567
USAF CB-10
V0098
Vidarabine
ZINC02169830
adenine-D-ribose
adenosine
b-D-Adenosine
beta-Adenosine
beta-D-Adenosine
beta-D-Ribofuranoside, adenine-9
beta-delta-Adenosine
bmse000061
nchembio.143-comp9
nchembio.186-comp109
nchembio.2007.56-comp13
nchembio.64-comp4
nchembio706-5
9dexetimide50021888-98-2
10
Citalopram50059729-33-82771
Synonyms:
1,3-Dihydro-1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-5-isobenzofurancarbonitrile
1,3-dihydro[3,4]benzofuran-5-carbonitrile
1-(3-(Dimethylamino)propyl)-1-(p-fluorophenyl)-5-phthalancarbonitrile
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile
59729-33-8
AB00513896
AC-12214
AC1L1EFH
AE-641/00603021
Akarin
BPBio1_000929
BRD-A47598013-004-02-0
BSPBio_000843
Bonitrile
C07572
C20H21FN2O
CHEBI:3723
CHEMBL549
CID2771
CPD000465669
Celapram
Celexa
Celius
Ciazil
Cilift
Cipram
Cipramil
Ciprapine
Citabax
Citadur
Citadur (TN)
Citalec
Citalopram (USP/INN)
Citalopram Hydrobromide
Citalopram [Celexa]
Citalopram [INN:BAN]
Citalopram hydrobromide
Citalopramum
Citalopramum [INN-Latin]
 
Citol
Citopam
Citox
Citrol
Cytalopram
D07704
DB00215
Dalsan
EINECS 261-891-1
Elopram
HMS2090O09
HMS2093A14
Humorup
I01-0382
InChI=1/C20H21FN2O/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20/h4-9,12H,3,10-11,14H2,1-2H3
L001223
LS-84327
Lopac0_000258
Lu 10-171
Lu-10-171
MolPort-003-666-794
NCGC00015267-07
NCGC00025160-02
Nitalapram
Oropram
Pramcit
Prestwick3_000692
Recital
SAM002589960
ST069372
STL058639
Seropram
Talam
Talohexal
Temperax
UNII-0DHU5B8D6V
Vodelax
Zentius
Zetalo
[3H]Citalopram
citalopram
11
CaffeineNutraceutical35858-08-22519
Synonyms:
07E4FB58-FD79-4175-8E3D-05BF96954522
1,3,7-Trimethyl-2,6-dioxopurine
1,3,7-Trimethyl-3,7-dihydro-1H-purine-2,6-dione
1,3,7-Trimethylpurine-2,6-dione
1,3,7-Trimethylxanthine
1,3,7-trimethylpurine-2,6-dione
1,3,7-trimethylxanthine
1-3-7-TRIMETHYLXANTHINE
1-Methyl-Theobromine
1-methyltheobromine
137X
1gfz
1l5q
1l7x
27602_FLUKA
2a3b
3,7-Dihydro-1,3,7-trimethyl-1H-purin-2,6-dion
3,7-Dihydro-1,3,7-trimethyl-1H-purine-2,6-dione
3,7-dihydro-1,3,7-trimethyl-1H-purine
5-26-13-00558 (Beilstein)
58-08-2
7-Methyl Theophylline
7-Methyltheophylline
7-methyltheophylline
71701-02-5
75035_FLUKA
95789-13-2
A.S.A. and Codeine Compound
AC-12774
AC1L1DV2
AC1Q3Z23
ACon1_000085
AI3-20154
AKOS000121334
Alert-Pep
Alert-pep
Anacin Maximum Strength
Anhydrous caffeine
Anhydrous caffeine (JP15)
Anhydrous caffeine (TN)
Anoquan
BIDD:ER0554
BIDD:GT0632
BIDD:PXR0172
BIM-0050216.0001
BRD-K02404261-001-02-7
BRD-K02404261-001-03-5
BRN 0017705
BSPBio_001921
Berlin-Chemie Brand of Caffeine
Bio-0579
Bio1_000473
Bio1_000962
Bio1_001451
Bristol-Myers Squibb Brand of Caffeine
C 0750
C07481
C0750_SIAL
C1778_SIAL
C2042
C6035_FLUKA
C6035_SIGMA
C7731_SIAL
C8960_SIAL
CCRIS 1314
CFF
CHEBI:27732
CHEMBL113
CID2519
CU-01000012617-3
Cafamil
Cafcit
Cafecon
Cafeina
Cafergot
Cafeína
Caffedrine
Caffedrine Caplets
Caffein
Caffeina
Caffeina [Italian]
Caffeine
Caffeine (USP)
Caffeine (natural)
Caffeine Pure
Caffeine [BAN:JAN]
Caffeine solution
Caffeine, Anhydrous
Caffeine, Monohydrate
Caffeine, Synthetic
Caffeine, anhydrous
Caffeine, synthetic
Caffine
Cafipel
Caféine
Coffein
Coffein [German]
Coffeine
Coffeinum
Coffeinum N
Coffeinum Purrum
Compound 65
D002110
D00528
DB00201
DHC Plus
DHCplus
Darvon Compound
Darvon Compound-65
Dasin
Dexitac
Dexitac Stay Alert Stimulant
Dhc Plus
Diurex
DivK1c_000730
Durvitan
EINECS 200-362-1
EU-0100228
Eldiatric C
Enerjets
Ercatab
Esgic
Esgic-Plus
FEMA No. 2224
Femcet
Fioricet
Fiorinal
GlaxoSmithKline Brand of Caffeine
Guaranine
HMS1920I09
HMS2091O11
HMS502E12
HSDB 36
Hycomine
Hycomine Compound
I14-4386
IDI1_000730
 
Invagesic
Invagesic Forte
KBio1_000730
KBio2_001781
KBio2_004349
KBio2_006917
KBio3_001141
KBioGR_002325
KBioSS_001781
Keep Alert
Kofein
Kofein [Czech]
Koffein
Koffein [German]
L000155
LS-237
Lanorinal
Lopac-C-0750
Lopac0_000228
MEGxp0_001350
MLS001055341
MLS001056714
MLS001066409
Mateina
Mateína
Maximum Strength Snapback Stimulant Powders
Medigesic Plus
Merck dura Brand of Caffeine
Methyltheobromide
Methyltheobromine
Methylxanthine theophylline
Midol Maximum Strength
Migergot
Miudol
MolMap_000054
MolPort-000-730-850
Monohydrate Caffeine
Monomethyl Derivative of Theophylline
Monomethyl derivative of Theophylline
NCGC00015208-01
NCGC00015208-02
NCGC00015208-04
NCGC00015208-14
NCGC00090699-01
NCGC00090699-02
NCGC00090699-03
NCGC00090699-04
NCGC00090699-05
NCGC00090699-06
NCGC00090699-07
NCGC00090699-08
NCGC00090699-09
NCGC00168808-01
NCGC00168808-02
NCI-C02733
NCIOpen2_008255
NINDS_000730
NSC 5036
NSC5036
Natural Caffeinum
Nix Nap
No Doz
No-Doz
Nodaca
Nodoz Maximum Strength Caplets
Norgesic
Norgesic Forte
Organex
Orphengesic
Orphengesic Forte
P-A-C Analgesic Tablets
PDSP1_001016
PDSP1_001235
PDSP2_001000
PDSP2_001219
Passauer Brand of Caffeine
Pep-Back
Percoffedrinol N
Percutafeine
Phensal
Pierre Fabre Brand of Caffeine
Probes1_000150
Probes2_000128
Propoxyphene
Propoxyphene Compound 65
Propoxyphene Compound-65
Quick Pep
Quick-Pep
Refresh'n
Republic Drug Brand of Caffeine
SDCCGMLS-0064595.P001
SDCCGMLS-0064595.P002
SK 65 Compound
SK-65 Compound
SMR000326667
SPBio_001222
SPECTRUM1500155
STK177283
Seid Brand of Caffeine
Spectrum2_001261
Spectrum3_000321
Spectrum4_001782
Spectrum5_000423
Spectrum_001301
Stim
Synalgos-Dc
TNP00310
Teina
Thein
Theine
Theobromine ME
Theobromine Me
Theophylline ME
Theophylline Me
Theophylline, 7-methyl
Thompson Brand 1 of Caffeine
Thompson Brand 2 of Caffeine
Tirend
Tri-Aqua
Triad
UNII-3G6A5W338E
Ultra Pep-Back
Vivarin
W222402_ALDRICH
WLN: T56 BN DN FNVNVJ B1 F1 H1
Wake-Up
Wigraine
Xanthine, 1,3,7-trimethyl
ZINC00001084
bmse000206
cafeine
caffeine
caffenium
component of Cafergot
nchembio.243-comp7
nchembio.63-comp5
nchembio774-comp2
teina

Interventional clinical trials:

(show all 49)
idNameStatusNCT IDPhase
1Long Term Treatment of Panic Disorder With Clonazepam or ParoxetineCompletedNCT02852577Phase 4
2A Study Of Sertraline Compared With Paroxetine In The Treatment Of Panic DisorderCompletedNCT00677352Phase 4
3Paroxetine vs Placebo Combined With Aerobic Exercise or Relaxation in Panic DisorderCompletedNCT00540098Phase 4
4Sertraline in Generalized Social Phobia With Co-Occurring Anxiety and Mood DisordersRecruitingNCT00182533Phase 4
5Lisdexamfetamine Dimesylate in the Treatment of Adult ADHD With Anxiety Disorder ComorbidityRecruitingNCT01863459Phase 4
6A Study To Assess the Safety of Extended Release Alprazolam for the Treatment of Adolescents With Panic Disorder or Anxiety With Panic AttacksTerminatedNCT00634790Phase 4
7Virtual Reality Exposure Therapy in Agoraphobic ParticipantsCompletedNCT00734370Phase 2, Phase 3
8Treatment of Panic Disorder: Long Term StrategiesCompletedNCT00000368Phase 3
9Comparison of Psychotherapy Programs to Treat Panic DisorderCompletedNCT00353470Phase 3
10Effects of Prismatic Spectacle Lenses on Symptoms of Dizziness, Headache and Anxiety as Caused by Vertical HeterophoriaCompletedNCT00785135Phase 3
11Internet-Versus Group-Administered Cognitive Behavior Therapy for Panic DisorderCompletedNCT00845260Phase 3
12Treatment of Social Phobia and Panic Disorder in AdultsCompletedNCT00619138Phase 3
13Mechanisms of Panic Disorders TreatmentRecruitingNCT01323556Phase 2, Phase 3
14Psychotherapy Outcome and Self-selection Effects in Panic DisorderRecruitingNCT01606592Phase 2, Phase 3
15Augmentation of Psychotherapy With D-Cycloserine in AgoraphobiaCompletedNCT01928823Phase 2
16Effectiveness of Intensive Cognitive Behavioral Therapy in Treating Adolescent Panic Disorder and AgoraphobiaCompletedNCT00576719Phase 2
17Exposure Therapy for Fear of Falling in Older AdultsCompletedNCT01609322Phase 2
18Physical Exercise Versus Cognitive-behavioral Therapy (CBT) for Panic Disorders: A Randomised Controlled TrialCompletedNCT01076777Phase 2
19Effectiveness of Cognitive Behavioral Therapy With Panic Control Treatment for Adolescents With Panic DisorderCompletedNCT00705380Phase 2
20Cognitive Behavior Therapy vs Exposure in Vivo in the Treatment of Panic Disorder With AgoraphobiaRecruitingNCT01680237Phase 2
21Improve: Integrating Emotion Focused Components Into Psychological TherapyRecruitingNCT02822443Phase 2
22An Bioequivalence Study Of Xanax Extended Release Tablets From Two Different Manufacturing SitesCompletedNCT01330472Phase 1
23Youth Mayo Clinic Anxiety Coach Randomized Controlled TrialNot yet recruitingNCT02205203Phase 1
24Physical Activity and Cognitive Behavioural Therapy in Panic Disorder and AgoraphobiaCompletedNCT01928810
25Thought Field Therapy and Cognitive Therapy for AgoraphobiaCompletedNCT00932919
26Longterm Outcome of Inpatient Cognitive and Behavioral Therapies for AgoraphobiaCompletedNCT01446172
27Can Thought Field Therapy (TFT) be Helpful for Patients With an Anxiety Disorder?CompletedNCT00202709
28Pilot Study of Vestibular Rehabilitation Training for Panic Disorder With Vestibular DysfunctionCompletedNCT00004366
29Cognitive Behavioral Therapy in Panic DisorderCompletedNCT00772746
30Physical Activity and Cognitive Behavioural Therapy in Panic DisorderCompletedNCT01788800
31Cognitive Behavior Psychotherapy in Panic DisorderCompletedNCT01025908
32Vestibular Dysfunction In Adult Patients With Panic Disorder With or Without AgoraphobiaCompletedNCT00004367
33Interpretation Modification Program for Social PhobiaCompletedNCT00684541
34Study of the Changes in Metabolic Parameters in Patients Treated With Escitalopram for Six MonthsCompletedNCT00711737
35Assessment of the Prevalence of Major Psychiatric Disorders in a Cohort of Women With Clinical Criteria Corresponding to Pure, Abortive-form, Obstetrical, Antiphospholipid SyndromeCompletedNCT02833194
36Validity of a Self-administered Questionnaire to Screen Phobia of Falling in the ElderlyCompletedNCT02387047
37Genetic Causes of Panic DisorderCompletedNCT00083265
38Providing Tools for Effective Care and Treatment of Anxiety DisordersRecruitingNCT02605668
39Building an Outcomes Assessment Infrastructure to Assess Anxiety TreatmentRecruitingNCT02305537
40Effectiveness of Cognitive Behavioral Short-term Treatment for Adolescents With Emotional Symptom Problems in Community Clinics in NorwayRecruitingNCT02150265
41Expectation of Unpleasant Events in Anxiety DisordersRecruitingNCT00055224
42Virtual Reality and Concept of Control in the Treatment of AcrophobiaRecruitingNCT02020824
43Effectiveness of a Transdiagnostic Internet-based Treatment for Emotional DisordersRecruitingNCT02345668
44Efficacy of a Transdiagnostic Internet-based Protocol in Community SampleRecruitingNCT02578758
45A Randomised Feasibility Trial With Internet Based Self-help TherapyRecruitingNCT02499055
46Study of Virtual Reality Therapy and Cognitive Behavior Therapy in Panic Disorder With AgoraphobiaActive, not recruitingNCT00129610
47Youth Mayo Clinic Anxiety Coach Pilot StudyEnrolling by invitationNCT02205177
48Clinical Trial of Transdiagnostic Cognitive-Behavior Therapy for Anxiety DisordersNot yet recruitingNCT02811458
49Dimensional Brain Behavior Predictors of CBT Outcomes in Pediatric AnxietyNot yet recruitingNCT02810171

Search NIH Clinical Center for Agoraphobia

Inferred drug relations via UMLS66/NDF-RT44:


Cochrane evidence based reviews: agoraphobia

Genetic Tests for Agoraphobia

About this section

Anatomical Context for Agoraphobia

About this section

MalaCards organs/tissues related to Agoraphobia:

34
Brain, Thyroid, Cortex, Pituitary, Cingulate cortex, Amygdala

Animal Models for Agoraphobia or affiliated genes

About this section

MGI Mouse Phenotypes related to Agoraphobia:

39
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053867.6CCKBR, GRPR, HTR1A, MAOA, OPRK1, RGS2
2MP:00036317.1CCKBR, HTR1A, MAOA, PTK7, RGS2, SLC6A4
3MP:00053856.9CCKBR, HTR1A, MAOA, PTK7, RGS2, SLC6A4

Publications for Agoraphobia

About this section

Articles related to Agoraphobia:

(show top 50)    (show all 539)
idTitleAuthorsYear
1
The role of treatment delivery factors in exposure-based cognitive behavioral therapy for panic disorder with agoraphobia. (27235836)
2016
2
Agoraphobia and Melancholia: Thoughts on Milrod's "Emptiness in Agoraphobia Patients". (26263925)
2015
3
Predictors of short- and long-term avoidance in completers of inpatient group interventions for agoraphobia. (25917291)
2015
4
The neural representation of emotionally neutral faces and places in patients with panic disorder with agoraphobia. (24176537)
2014
5
Efficacy of a hybrid online training for panic symptoms and agoraphobia: study protocol for a randomized controlled trial. (25370504)
2014
6
Therapist effects and the outcome-alliance correlation in cognitive behavioral therapy for panic disorder with agoraphobia. (24275067)
2014
7
Predicting Treatment Response to Cognitive Behavioral Therapy in Panic Disorder With Agoraphobia by Integrating Local Neural Information. (25409415)
2014
8
Treatment Modality Preferences and Adherence to Group Treatment for Panic Disorder with Agoraphobia. (24136085)
2013
9
Late-onset agoraphobia: general population incidence and evidence for a clinical subtype. (23820832)
2013
10
Antianxiety medications for the treatment of complex agoraphobia: pharmacological interventions for a behavioral condition. (22090798)
2011
11
Nomophobia: the mobile phone in panic disorder with agoraphobia: reducing phobias or worsening of dependence? (20299865)
2010
12
Anxiogenic properties of a computer simulation for panic disorder with agoraphobia. (20100626)
2010
13
A randomized, controlled clinical trial of standard, group and brief cognitive-behavioral therapy for panic disorder with agoraphobia: a two-year follow-up. (19709851)
2009
14
Mechanisms of change in cognitive therapy for panic disorder with agoraphobia. (17727812)
2008
15
Anxiety sensitivity: a missing piece to the agoraphobia-without-panic puzzle. (17307933)
2007
16
Cognitive-behavioral group treatment for panic disorder with agoraphobia. (17279533)
2007
17
"My new Alfa Romeo GT is not in the garage any more": Cognitive behavioural therapy of panic disorder with agoraphobia co morbid with psychosis. (17099612)
2006
18
Selective cognitive deficits in obsessive-compulsive disorder compared to panic disorder with agoraphobia. (15667435)
2005
19
Increased probability of remaining in remission from panic disorder with agoraphobia after drug treatment in patients who received concurrent cognitive-behavioural therapy: a follow-up study. (12466636)
2003
20
Are benzodiazepines still the medication of choice for patients with panic disorder with or without agoraphobia? (12900305)
2003
21
Perceived criticism predicts severity of anxiety symptoms after behavioral treatment in patients with obsessive-compulsive disorder and panic disorder with agoraphobia. (12652634)
2003
22
Clinical and psychosocial outcome of patients affected by panic disorder with or without agoraphobia: results from a naturalistic follow-up study. (12547305)
2002
23
12-month prevalence of panic disorder with or without agoraphobia in the Swedish general population. (12107711)
2002
24
2nd year maintenance and discontinuation of imipramine in panic disorder with agoraphobia. (11534926)
2001
25
The development of agoraphobia in panic disorder: a predictable process? (10760557)
2000
26
Preattentive bias for emotional information in panic disorder with agoraphobia. (10369032)
1999
27
Long-term maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia. (12884888)
1999
28
The differential effect of personality on computer-based treatment of agoraphobia. (9777283)
1998
29
The role of trauma and dissociation in cognitive-behavioral psychotherapy outcome and maintenance for panic disorder with agoraphobia. (9737056)
1998
30
Follow-up on the treatment of panic disorder with or without agoraphobia: a quantitative review. (9680042)
1998
31
Embarrassment about the first panic attack predicts agoraphobia in panic disorder patients. (9159975)
1997
32
The benefit of an insight-oriented and experiential approach on panic and agoraphobia symptoms. Results of a controlled comparison of client-centered therapy alone and in combination with behavioral exposure. (9403918)
1997
33
Does preference for type of treatment matter? A study of exposure in vivo with or without hypnosis in the treatment of panic disorder with agoraphobia. (9086865)
1997
34
Life events and panic disorder/agoraphobia. (7758297)
1995
35
Exposure reduced agoraphobia but not panic, and cognitive therapy reduced panic but not agoraphobia. (7910732)
1994
36
DSM-III personality disorders in generalized anxiety, panic/agoraphobia, and obsessive-compulsive disorders. (8348802)
1993
37
Agoraphobia without panic: clinical reappraisal of an epidemiologic finding. (8379553)
1993
38
The association of panic/agoraphobia and asthma. Contributing factors and clinical implications. (1473713)
1992
39
Use of medical services and treatment for panic disorder with agoraphobia and for social phobia. (1525731)
1992
40
The genetic epidemiology of phobias in women. The interrelationship of agoraphobia, social phobia, situational phobia, and simple phobia. (1558461)
1992
41
Biological correlates of panic disorder with agoraphobia: practice perspectives for nurses. (1759863)
1991
42
A comparison of DSM-III personality disorders in panic/agoraphobia and obsessive-compulsive disorder. (2340718)
1990
43
Panic attacks and agoraphobia: low dose clomipramine treatment. (2651491)
1989
44
Relationships among measures of communication, marital satisfaction and exposure during couples treatment of agoraphobia. (2564773)
1989
45
Late-life onset of panic disorder with agoraphobia in three patients. (2742018)
1989
46
The cause and treatment of agoraphobia. (2895623)
1988
47
Autonomic changes after treatment of agoraphobia with panic attacks. (3393620)
1988
48
The relationship between panic, phobic and anticipatory anxiety in agoraphobia. (3044349)
1988
49
The role of expectancy in exposure-generated fear reduction in agoraphobia. (3365201)
1988
50
Agoraphobia and parental bereavement. (3435374)
1987

Variations for Agoraphobia

About this section

Expression for genes affiliated with Agoraphobia

About this section
Search GEO for disease gene expression data for Agoraphobia.

Pathways for genes affiliated with Agoraphobia

About this section

Pathways related to Agoraphobia according to GeneCards Suite gene sharing:

idSuper pathwaysScoreTop Affiliating Genes
1
Show member pathways
9.7MAOA, SLC6A4
29.4HTR1A, MAOA, SLC6A4
39.4HTR1A, MAOA, SLC6A4

GO Terms for genes affiliated with Agoraphobia

About this section

Cellular components related to Agoraphobia according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1neuron projectionGO:00430059.1OPRK1, RGS2, SLC6A4, STMN1
2integral component of plasma membraneGO:00058877.8CCKBR, GRPR, HTR1A, OPRK1, PTK7, SLC6A4
3plasma membraneGO:00058866.9CCKBR, GRPR, HTR1A, OPRK1, PTK7, RGS2

Biological processes related to Agoraphobia according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1vasoconstrictionGO:004231010.1HTR1A, SLC6A4
2serotonin metabolic processGO:00424289.9HTR1A, MAOA
3sensory perceptionGO:00076009.7CCKBR, OPRK1
4cellular response to retinoic acidGO:00713009.4PTK7, SLC6A4
5phospholipase C-activating G-protein coupled receptor signaling pathwayGO:00072009.2CCKBR, OPRK1

Sources for Agoraphobia

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
25GTR
26HGMD
27HMDB
28ICD10
29ICD10 via Orphanet
30ICD9CM
31IUPHAR
32KEGG
35MedGen
37MeSH
38MESH via Orphanet
39MGI
42NCI
43NCIt
44NDF-RT
47NINDS
48Novoseek
50OMIM
51OMIM via Orphanet
55PubMed
56QIAGEN
61SNOMED-CT via Orphanet
65Tumor Gene Family of Databases
66UMLS
67UMLS via Orphanet